Genespire claims one of Italian biotech’s biggest fundraisers yet
Italian biotech Genespire - which is developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases - has announced the closing of a 46.6 million euros ($52 million) Series B financing.
The round - one of the largest private Italian biotech company financings to date - was co-led by Sofinnova Partners, XGEN Venture and CDP Venture Capital through its large venture fund forming a strong syndicate with Indaco SGR.
This financing will enable the development of GENE202, the company’s lead candidate, up to a Phase I/II trial. The gene therapy is in development for the treatment of methylmalonic acidemia (MMA), a devastating genetic disorder impairing the metabolism of certain amino acids and fats.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze